Expanding into Digital Assets and DeFi SARASOTA, FL, August 5, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) has announced a new strategy focused on building a cryptocurrency reserve. The program will initially target prominent digital currencies like Bitcoin, Ethereum, and Solana. The company intends to strategically acquire these assets and utilize staking mechanisms to generate income while prioritizing capital safety and potential asset value increases. The scale of this initiative will depend on available funds and overall market conditions. To spearhead this venture, Silo Pharma has welcomed Corwin Yu, a recognized leader in digital asset technology, as the inaugural member of its newly established Crypto Advisory Board. Furthermore, Silo Pharma has invested in AI-driven market intelligence tools to provide the team with up-to-the-minute data, potentially improving the speed and quality of decision-making. “Given the recent success of corporate cryptocurrency treasury programs and the growing influx of capital into digital assets, we see a potential opportunity to generate and unlock sustainable value for Silo’s shareholders, effective immediately,” stated Eric Weisblum, CEO of Silo Pharma. “We are very pleased to welcome Corwin Yu as our chief strategic advisor, leading a newly formed advisory board of three members. The remaining two positions will be filled in the future.” Corwin Yu brings over two decades of experience in developing and managing mission-critical systems for the financial industry. Currently, Mr. Yu holds the position of Global Head of Digital Assets at TSImagine, a leading fintech company. Previously, he was the founding Chief Technology Officer of MARKTS, a pioneering institutional crypto trading platform. His extensive experience also includes roles at PIMCO, Credit Suisse, hedge funds, and other digital asset firms. Mr. Yu possesses a strong track record in creating cryptocurrency trading infrastructure, managing funds, and ensuring regulatory compliance. He has substantial experience in deploying scalable cloud-based platforms and overseeing diverse trading strategies. He is credited with building and expanding digital asset trading platforms, leading global engineering and DevOps teams, and implementing secure and compliant solutions for crypto storage and treasury management. “While launching this digital asset treasury strategy, we remain focused on our core biopharmaceutical business, which is dedicated to developing innovative treatments for unmet medical needs,” Mr. Weisblum added. “Our leading candidate, SPC-15 for PTSD, is completing its final pre-submission studies prior to filing an Investigational New Drug (IND) application with the FDA. Upon approval, we anticipate commencing a Phase 1 clinical trial in humans.” About Silo Pharma Silo Pharma operates as both a biopharmaceutical and a cryptocurrency treasury company in the developmental stage. The company focuses on developing therapies for underserved conditions, including psychiatric disorders linked to stress, chronic pain, and diseases affecting the central nervous system (CNS). The company’s pipeline includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical programs targeting Alzheimer’s disease and multiple sclerosis. Silo Pharma collaborates with leading universities and laboratories in its research endeavors. Forward-Looking Statements This communication contains predictions and expectations defined as “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. These statements can be identified by words like “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” and “potential,” among other similar expressions. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Silo Pharma, Inc.’s (“Silo” or “the Company”) actual performance to be materially different from those anticipated. These risks include, but aren’t limited to, fluctuations in projected revenues, evolving economic and competitive landscapes, difficulties in advancing the company’s tech, customer acquisition and retention, shifts in customer spending, and other operational challenges. Therefore, although the Company believes its assumptions are reasonable, there’s no guarantee these expectations will materialize. The Company doesn’t commit to updating or revising forward-looking statements due to new information, future events, or other changes, except where legally required. Contact 800-705-0120 [email protected]